Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 5765
  • Home
  • Print this page
  • Email this page

    Article Cited by others

REVIEW ARTICLE

Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer

Dine Jennifer, Gordon RuthAnn, Shames Yelena, Kasler Mary Kate, Barton-Burke Margaret

Year : 2017| Volume: 4| Issue : 2 | Page no: 127-135

   This article has been cited by
 
1 B Cells in Atherosclerosis
Tanyaporn Pattarabanjird,Cynthia Li,Coleen McNamara
JACC: Basic to Translational Science. 2021; 6(6): 546
[Pubmed]  [Google Scholar] [DOI]
2 Current immunotherapy in gastrointestinal malignancies A Review
Dushyant Singh Dahiya,Asim Kichloo,Jagmeet Singh,Michael Albosta,Manidhar Lekkala
Journal of Investigative Medicine. 2021; 69(3): 689
[Pubmed]  [Google Scholar] [DOI]
3 Immunological and biological dissection of normal and tumoral salivary glands
Mohammad Reza Haghshenas,Hamid Ghaderi,Hossein Daneste,Abbas Ghaderi
International Reviews of Immunology. 2021; : 1
[Pubmed]  [Google Scholar] [DOI]
4 A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers
Safiye Akkin,Gamze Varan,Erem Bilensoy
Molecules. 2021; 26(11): 3382
[Pubmed]  [Google Scholar] [DOI]
5 CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway
Elisabet Ampudia-Mesias,Francisco Puerta-Martinez,Miurel Bridges,David Zellmer,Andrew Janeiro,Matt Strokes,Yuk Y. Sham,Ayman Taher,Maria Castro,Christopher L. Moertel,G. Elizabeth Pluhar,Michael R. Olin
Neurotherapeutics. 2021;
[Pubmed]  [Google Scholar] [DOI]
6 Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer
Nilay Sengul Samanci,Duygu Ilke Cikman,Kerem Oruc,Sahin Bedir,Emir Çelik,Ezgi Degerli,Sumeyra Derin,Fuat Hulusi Demirelli,Mustafa Özgüroglu
Tumori Journal. 2021; 107(4): 304
[Pubmed]  [Google Scholar] [DOI]
7 Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics
Ambika Chamoli,Abhishek S. Gosavi,Urjita P. Shirwadkar,Khushal V. Wangdale,Santosh Kumar Behera,Nawneet Kumar Kurrey,Kiran Kalia,Amit Mandoli
Oral Oncology. 2021; 121: 105451
[Pubmed]  [Google Scholar] [DOI]
8 Emerging targets for anticancer vaccination: PD-1
J. Tobias,P. Steinberger,M. Drinic,U. Wiedermann
ESMO Open. 2021; 6(5): 100278
[Pubmed]  [Google Scholar] [DOI]
9 Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis
Atsushi Yamaguchi,Yoshitaka Saito,Keisuke Okamoto,Katsuya Narumi,Ayako Furugen,Yoh Takekuma,Mitsuru Sugawara,Masaki Kobayashi
Supportive Care in Cancer. 2021;
[Pubmed]  [Google Scholar] [DOI]
10 Ocular surface disease associated with immune checkpoint inhibitor therapy
Royce B. Park,Sandeep Jain,Hui Han,Jennifer Park
The Ocular Surface. 2021;
[Pubmed]  [Google Scholar] [DOI]
11 Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression
Ramesh Butti,Ramakrishna Nimma,Gautam Kundu,Anuradha Bulbule,Totakura V. S. Kumar,Vinoth Prasanna Gunasekaran,Deepti Tomar,Dhiraj Kumar,Anupama Mane,Satyajit S. Gill,Tushar Patil,Georg F. Weber,Gopal C. Kundu
Oncogene. 2021;
[Pubmed]  [Google Scholar] [DOI]
12 On-Chip Biogenesis of Circulating NK Cell-Derived Exosomes in Non-Small Cell Lung Cancer Exhibits Antitumoral Activity
Yoon-Tae Kang,Zeqi Niu,Thomas Hadlock,Emma Purcell,Ting-Wen Lo,Mina Zeinali,Sarah Owen,Venkateshwar G. Keshamouni,Rishindra Reddy,Nithya Ramnath,Sunitha Nagrath
Advanced Science. 2021; : 2003747
[Pubmed]  [Google Scholar] [DOI]
13 Immunotherapy Assessment: Using a Survey Instrument to Examine Oncology Nurses’ Confidence Levels With Administration and Management
Barbara Offner,Lisa Rinke
Clinical Journal of Oncology Nursing. 2021; 25(3): 343
[Pubmed]  [Google Scholar] [DOI]
14 Immune classification of osteosarcoma
Trang Le,Sumeyye Su,Leili Shahriyari
Mathematical Biosciences and Engineering. 2021; 18(2): 1879
[Pubmed]  [Google Scholar] [DOI]
15 T-Cell-Derived Nanovesicles for Cancer Immunotherapy
Jihye Hong,Mikyung Kang,Mungyo Jung,Yun Young Lee,Yongbum Cho,Cheesue Kim,Seuk Young Song,Chun Gwon Park,Junsang Doh,Byung-Soo Kim
Advanced Materials. 2021; : 2101110
[Pubmed]  [Google Scholar] [DOI]
16 Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer
Adi Kartolo,Ryan Holstead,Sidra Khalid,Jeffrey Emack,Wilma Hopman,Tara Baetz
Journal of Immunotherapy. 2021; 44(1): 41
[Pubmed]  [Google Scholar] [DOI]
17 Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
Giandomenico Roviello,Martina Catalano,Stefania Nobili,Raffaella Santi,Enrico Mini,Gabriella Nesi
International Journal of Molecular Sciences. 2020; 21(21): 7935
[Pubmed]  [Google Scholar] [DOI]
18 Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database
Shiori Hasegawa,Hiroaki Ikesue,Satoshi Nakao,Kazuyo Shimada,Ririka Mukai,Mizuki Tanaka,Kiyoka Matsumoto,Misaki Inoue,Riko Satake,Yu Yoshida,Fumiya Goto,Tohru Hashida,Mitsuhiro Nakamura
Pharmacoepidemiology and Drug Safety. 2020;
[Pubmed]  [Google Scholar] [DOI]
19 Comprehensive Perspective for Lung Cancer Characterisation Based on AI Solutions Using CT Images
Tania Pereira,Cláudia Freitas,José Luis Costa,Joana Morgado,Francisco Silva,Eduardo Negrão,Beatriz Flor de Lima,Miguel Correia da Silva,António J. Madureira,Isabel Ramos,Venceslau Hespanhol,António Cunha,Hélder P. Oliveira
Journal of Clinical Medicine. 2020; 10(1): 118
[Pubmed]  [Google Scholar] [DOI]
20 Conjugation of biphenyl groups with poly(ethylene glycol) to enhance inhibitory effects on the PD-1/PD-L1 immune checkpoint interaction
Eun-Hye Kim,Boyang Ning,Masuki Kawamoto,Hideyuki Miyatake,Eiry Kobatake,Yoshihiro Ito,Jun Akimoto
Journal of Materials Chemistry B. 2020;
[Pubmed]  [Google Scholar] [DOI]
21 Cellular signalling pathways mediating the pathogenesis of chronic inflammatory respiratory diseases: an update
Meenu Mehta,Daljeet S. Dhanjal,Keshav R. Paudel,Bhupender Singh,Gaurav Gupta,S. Rajeshkumar,Lakshmi Thangavelu,Murtaza M. Tambuwala,Hamid A. Bakshi,Dinesh K. Chellappan,Parijat Pandey,Harish Dureja,Nitin B. Charbe,Sachin K. Singh,Shakti D. Shukla,Srinivas Nammi,Alaa A. Aljabali,Peter R. Wich,Philip M. Hansbro,Saurabh Satija,Kamal Dua
Inflammopharmacology. 2020;
[Pubmed]  [Google Scholar] [DOI]
22 Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials
Stéphane Faury,Jérôme Foucaud,Ali Montazeri
PLOS ONE. 2020; 15(1): e0227344
[Pubmed]  [Google Scholar] [DOI]
23 Domain binding and isotype dictate the activity of anti-human OX40 antibodies
Jordana Griffiths,Khiyam Hussain,Hannah L Smith,Theodore Sanders,Kerry L Cox,Monika Semmrich,Linda Mårtensson,Jinny Kim,Tatyana Inzhelevskaya,Chris A Penfold,Alison L Tutt,C Ian Mockridge,HT Claude Chan,Vikki English,Ruth F French,Ingrid Teige,Aymen Al-Shamkhani,Martin J Glennie,Bjorn L Frendeus,Jane E Willoughby,Mark S Cragg
Journal for ImmunoTherapy of Cancer. 2020; 8(2): e001557
[Pubmed]  [Google Scholar] [DOI]
24 Oncolytic viruses: what to expect from their use in cancer treatment
Maria Terrível,Catarina Gromicho,Ana Miguel Matos
Microbiology and Immunology. 2020;
[Pubmed]  [Google Scholar] [DOI]
25 Diagnosis and Management of Checkpoint Inhibitor Side Effects in Patients with Bladder Cancer: the Urologist’s Perspective
Neal Shore
Bladder Cancer. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
26 Human health and snails
Varun Dhiman,Deepak Pant
Journal of Immunoassay and Immunochemistry. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
27 Hybrid phenotype mining method for investigating off-target protein and underlying side effects of anti-tumor immunotherapy
Yuyu Zheng,Xiangyu Meng,Pierre Zweigenbaum,Lingling Chen,Jingbo Xia
BMC Medical Informatics and Decision Making. 2020; 20(S3)
[Pubmed]  [Google Scholar] [DOI]
28 Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators
Tilahun Ayane Debele,Cheng-Fa Yeh,Wen-Pin Su
Cancers. 2020; 12(12): 3773
[Pubmed]  [Google Scholar] [DOI]
29 The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy
Yuki Shinno,Yasushi Goto,Mayu Ohuchi,Akinobu Hamada,Hiroshi Nokihara,Yasuhiro Fujiwara,Yuichiro Ohe
JTO Clinical and Research Reports. 2020; 1(1): 100008
[Pubmed]  [Google Scholar] [DOI]
30 Management of the Adverse Effects of Immune Checkpoint Inhibitors
Manuel Morgado,Ana Plácido,Sandra Morgado,Fátima Roque
Vaccines. 2020; 8(4): 575
[Pubmed]  [Google Scholar] [DOI]
31 Recent advances in targeted nanomedicine as promising antitumor therapeutics
Siddhanth Hejmady,Rajesh Pradhan,Amit Alexander,Mukta Agrawal,Gautam Singhvi,Bapi Gorain,Sanjay Tiwari,Prashant Kesharwani,Sunil Kumar Dubey
Drug Discovery Today. 2020;
[Pubmed]  [Google Scholar] [DOI]
32 Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer
Marianne Davies,Emily Duffield
Clinical Journal of Oncology Nursing. 2020; 24(3): 277
[Pubmed]  [Google Scholar] [DOI]
33 Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide
Lucia Feni,Sara Parente,Clémence Robert,Silvia Gazzola,Daniela Arosio,Umberto Piarulli,Ines Neundorf
Bioconjugate Chemistry. 2019;
[Pubmed]  [Google Scholar] [DOI]
34 Landscape of Germline Mutations in DNA Repair Genes for Breast Cancer in Latin America: Opportunities for PARP-Like Inhibitors and Immunotherapy
Arash Urbina-Jara,Arash Rojas-Martinez,Arash Martinez-Ledesma,Arash Aguilar,Arash Villarreal-Garza,Arash Ortiz-Lopez
Genes. 2019; 10(10): 786
[Pubmed]  [Google Scholar] [DOI]
35 What can independent research for mesothelioma achieve to treat this orphan disease?
Alice Guazzelli,Parisa Meysami,Emyr Bakker,Ezio Bonanni,Constantinos Demonacos,Marija Krstic-Demonacos,Luciano Mutti
Expert Opinion on Investigational Drugs. 2019; : 1
[Pubmed]  [Google Scholar] [DOI]
36 Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer
Jin Sothornwit,Anakapong Phunmanee,Chatlert Pongchaiyakul
Frontiers in Endocrinology. 2019; 10
[Pubmed]  [Google Scholar] [DOI]
37 Tn antigen analogues: the synthetic way to “upgrade” an attracting tumour associated carbohydrate antigen (TACA)
Cristina Nativi,Francesco Papi,Stefano Roelens
Chemical Communications. 2019; 55(54): 7729
[Pubmed]  [Google Scholar] [DOI]
38 Iatrogenic CNS demyelination in the era of modern biologics
Neha Kumar,Hesham Abboud
Multiple Sclerosis Journal. 2019; 25(8): 1079
[Pubmed]  [Google Scholar] [DOI]
39 Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma
James Lopez,Naveen Yarlagadda,Zaid Gheith,Meera Mohan,Appalanaidu Sasapu
Baylor University Medical Center Proceedings. 2019; : 1
[Pubmed]  [Google Scholar] [DOI]
40 Effectiveness of Multi-Prognostic Index in older patients with advanced malignancies treated with immunotherapy
Andrea Sbrana,Rachele Antognoli,Giuseppe Pasqualetti,Giuseppe Linsalata,Chukwma Okoye,Valeria Calsolaro,Federico Paolieri,Francesco Bloise,Sergio Ricci,Andrea Antonuzzo,Fabio Monzani
Journal of Geriatric Oncology. 2019;
[Pubmed]  [Google Scholar] [DOI]
41 Recruiting monomer for dimer formation: resolving the antagonistic mechanisms of novel immune check point inhibitors against Programmed Death Ligand-1 in cancer immunotherapy
Opeyemi S. Soremekun,Fisayo A. Olotu,Clement Agoni,Mahmoud E. S. Soliman
Molecular Simulation. 2019; : 1
[Pubmed]  [Google Scholar] [DOI]
42 Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy,Chigozirim N. Ekeke,Kira L. Russell,Samuel C. Butler,Yue Wang,James D. Luketich,Adam C. Soloff,Rajeev Dhupar,Michael T. Lotze
OncoImmunology. 2019; : 1
[Pubmed]  [Google Scholar] [DOI]
43 Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers
Jitwadee Inthagard,Joanne Edwards,Antonia K. Roseweir
Clinical Science. 2019; 133(2): 181
[Pubmed]  [Google Scholar] [DOI]
44 Immunotherapy: last bullet in platinum refractory germ cell testicular cancer
Albert Semaan,Fady GH Haddad,Roland Eid,Hampig Raphael Kourie,Elie Nemr
Future Oncology. 2019; 15(5): 533
[Pubmed]  [Google Scholar] [DOI]
45 Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature
Spandana R. Kopalli,Tae-Bong Kang,Kwang-Ho Lee,Sushruta Koppula
Recent Patents on Anti-Cancer Drug Discovery. 2019; 14(2): 100
[Pubmed]  [Google Scholar] [DOI]
46 Preclinical Evaluation and Clinical Translation of Magnetite-Based Nanomedicines
Julia Nuzhina,Alexander A. Shtil,Artur Prilepskii,Vladimir V. Vinogradov
Journal of Drug Delivery Science and Technology. 2019; : 101282
[Pubmed]  [Google Scholar] [DOI]
47 Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Debarati Banik,Sara Moufarrij,Alejandro Villagra
International Journal of Molecular Sciences. 2019; 20(9): 2241
[Pubmed]  [Google Scholar] [DOI]
48 Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies
Shiao Li Oei,Anja Thronicke,Friedemann Schad
Evidence-Based Complementary and Alternative Medicine. 2019; 2019: 1
[Pubmed]  [Google Scholar] [DOI]
49 Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam,Vinay Prasad
JAMA Network Open. 2019; 2(5): e192535
[Pubmed]  [Google Scholar] [DOI]
50 Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments
Anusha Pusuluri,Debra Wu,Samir Mitragotri
Journal of Controlled Release. 2019;
[Pubmed]  [Google Scholar] [DOI]
51 Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy
Sri Murugan Poongkavithai Vadevoo,Smriti Gurung,Fatima Khan,Md. Enamul Haque,Gowri Rangaswamy Gunassekaran,Lianhua Chi,Uttapol Permpoon,Byungheon Lee
Archives of Pharmacal Research. 2019; 42(2): 150
[Pubmed]  [Google Scholar] [DOI]
52 Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy
Xinyu Ye,Xin Liang,Qian Chen,Qianwei Miao,Xiuli Chen,Xudong Zhang,Lin Mei
ACS Nano. 2019;
[Pubmed]  [Google Scholar] [DOI]
53 Immunotherapy in non-small cell lung cancer: The past, the present, and the future
Meng Lu,Yanjun Su
Thoracic Cancer. 2019;
[Pubmed]  [Google Scholar] [DOI]
54 Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy
Rama Soundararajan,Jared Fradette,Jessica Konen,Stacy Moulder,Xiang Zhang,Don Gibbons,Navin Varadarajan,Ignacio Wistuba,Debasish Tripathy,Chantale Bernatchez,Lauren Byers,Jeffrey Chang,Alejandro Contreras,Bora Lim,Edwin Parra,Emily Roarty,Jing Wang,Fei Yang,Michelle Barton,Jeffrey Rosen,Sendurai Mani
Cancers. 2019; 11(5): 714
[Pubmed]  [Google Scholar] [DOI]
55 Immunology and Immunotherapy in Critical Care: An Overview
Nancy Munro
AACN Advanced Critical Care. 2019; 30(2): 113
[Pubmed]  [Google Scholar] [DOI]
56 A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity
Tim S. Grant,Darren Burns,Christopher Kiff,Dawn Lee
PharmacoEconomics. 2019;
[Pubmed]  [Google Scholar] [DOI]
57 A Case of Severe Seronegative Inflammatory Arthritis due to Nivolumab and Review of the Literature
Bicky Thapa,Asad Ali,Raunak Nair,Rishik Vashisht,Cassandra Calabrese
Case Reports in Rheumatology. 2019; 2019: 1
[Pubmed]  [Google Scholar] [DOI]
58 Therapeutic vaccines for high-risk HPV-associated diseases
Aleyo Chabeda,Romana J.R. Yanez,Renate Lamprecht,Ann E. Meyers,Edward P. Rybicki,Inga I. Hitzeroth
Papillomavirus Research. 2018; 5: 46
[Pubmed]  [Google Scholar] [DOI]
59 Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary
Julie R. Brahmer,Christina Lacchetti,John A. Thompson
Journal of Oncology Practice. 2018; 14(4): 247
[Pubmed]  [Google Scholar] [DOI]
60 Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
Seok-Ho Shin,Min-Ho Park,Jin-Ju Byeon,Byeong Lee,Yuri Park,Nahye Kim,Jangmi Choi,Young Shin
Pharmaceutics. 2018; 10(4): 260
[Pubmed]  [Google Scholar] [DOI]
61 Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer,Christina Lacchetti,Bryan J. Schneider,Michael B. Atkins,Kelly J. Brassil,Jeffrey M. Caterino,Ian Chau,Marc S. Ernstoff,Jennifer M. Gardner,Pamela Ginex,Sigrun Hallmeyer,Jennifer Holter Chakrabarty,Natasha B. Leighl,Jennifer S. Mammen,David F. McDermott,Aung Naing,Loretta J. Nastoupil,Tanyanika Phillips,Laura D. Porter,Igor Puzanov,Cristina A. Reichner,Bianca D. Santomasso,Carole Seigel,Alexander Spira,Maria E. Suarez-Almazor,Yinghong Wang,Jeffrey S. Weber,Jedd D. Wolchok,John A. Thompson
Journal of Clinical Oncology. 2018; 36(17): 1714
[Pubmed]  [Google Scholar] [DOI]
62 Development of mRNA vaccines and their prophylactic and therapeutic applications
Kyuri Lee,Minjeong Kim,Yunmi Seo,Hyukjin Lee
Nano Research. 2018;
[Pubmed]  [Google Scholar] [DOI]
63 Checkpoint inhibitors: What gastroenterologists need to know
Monjur Ahmed
World Journal of Gastroenterology. 2018; 24(48): 5433
[Pubmed]  [Google Scholar] [DOI]
64 Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study
Ash Bullement,Nicholas R. Latimer,Helen Bell Gorrod
Value in Health. 2018;
[Pubmed]  [Google Scholar] [DOI]
65 Diagnostik und Therapie von immunvermittelten Nebenwirkungen durch Checkpointinhibitoren in der Intensivmedizin
Y. d’Hargues,J. Prinz,P. Gödel,A. Shimabukuro-Vornhagen,M. Kochanek,B. Böll
Medizinische Klinik - Intensivmedizin und Notfallmedizin. 2018;
[Pubmed]  [Google Scholar] [DOI]
66 Ex Vivo Tumor-on-a-Chip Platforms to Study Intercellular Interactions within the Tumor Microenvironment
Vardhman Kumar,Shyni Varghese
Advanced Healthcare Materials. 2018; : 1801198
[Pubmed]  [Google Scholar] [DOI]
67 A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Ash Bullement,Yang Meng,Miranda Cooper,Dawn Lee,Tara Louise Harding,Chris O’Regan,Raquel Aguiar-Ibanez
Journal of Medical Economics. 2018; : 1
[Pubmed]  [Google Scholar] [DOI]
68 Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches
Nasser Hashemi Goradel,Nasir Mohajel,Ziba Veisi Malekshahi,Samira Jahangiri,Masoud Najafi,Bagher Farhood,Keywan Mortezaee,Babak Negahdari,Arash Arashkia
Journal of Cellular Physiology. 2018;
[Pubmed]  [Google Scholar] [DOI]
69 Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo,Bhagirathbhai Dholaria,Aixa E. Soyano,Keith L. Knutson,Saranya Chumsri,Yanyan Lou
Journal of Hematology & Oncology. 2018; 11(1)
[Pubmed]  [Google Scholar] [DOI]
70 Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment
Jialing Zhang,Stephan Stanislaw Späth,Sadie L Marjani,Wengeng Zhang,Xinghua Pan
Precision Clinical Medicine. 2018; 1(1): 29
[Pubmed]  [Google Scholar] [DOI]
71 A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity
Prabhakaran Kumar,Palash Bhattacharya,Bellur S. Prabhakar
Journal of Autoimmunity. 2018;
[Pubmed]  [Google Scholar] [DOI]
72 Addressing New Diagnostic and Treatment Challenges Associated With a New Age of Cancer Treatment
Jason J. Bischof,Carolyn J. Presley,Jeffrey M. Caterino
Annals of Emergency Medicine. 2018;
[Pubmed]  [Google Scholar] [DOI]
73 Immunotherapy Adverse Events, Part 2: The Role of the Primary Care Nurse Practitioner
Fedricker D. Barber
The Journal for Nurse Practitioners. 2018;
[Pubmed]  [Google Scholar] [DOI]
74 Guillain-Barré-like syndrome during pembrolizumab treatment
Stephanie Ong,James Chapman,Gavin Young,Talal Mansy
Muscle & Nerve. 2018;
[Pubmed]  [Google Scholar] [DOI]
75 Data-Driven Methods for Advancing Precision Oncology
Prema Nedungadi,Akshay Iyer,Georg Gutjahr,Jasmine Bhaskar,Asha B. Pillai
Current Pharmacology Reports. 2018;
[Pubmed]  [Google Scholar] [DOI]
76 Nano-pulse stimulation induces potent immune responses, eradicating local breast cancer while reducing distant metastases
Siqi Guo,Yu Jing,Niculina I. Burcus,Brittany P. Lassiter,Royena Tanaz,Richard Heller,Stephen J. Beebe
International Journal of Cancer. 2017;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article